Ratta Raffaele, Santini Daniele
Tumori. 2014 Mar-Apr;100(2):e59-62. doi: 10.1177/030089161410000227.
Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. At the moment several biological agents are used for the treatment of metastatic renal cell carcinoma. We describe the case of a man who has been treated with pazopanib (Votrient) for metastatic renal cell carcinoma since July 2011. At the time of writing, the patient is still receiving treatment (29 months) and is showing a long-lasting response with a favorable safety profile. This is an excellent example of chronic neoplastic disease in a patient who can be defined as long-surviving.
肾细胞癌是成人中最常见的肾癌类型。它约占成人恶性肿瘤的3%，以及肾脏肿瘤的90 - 95%。目前有几种生物制剂用于治疗转移性肾细胞癌。我们描述了一名自2011年7月起接受帕唑帕尼（维全特）治疗转移性肾细胞癌的男性病例。在撰写本文时，该患者仍在接受治疗（29个月），并表现出持久的反应且安全性良好。这是一名可被定义为长期存活患者的慢性肿瘤疾病的极佳例子。
